Terumo Corporation
OTCPK:TRUM.F Stok Raporu
Terumo Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 4/6 Terumo kazançlarla iyi bir şekilde karşılanan, 0.86% cari getiriye sahip, temettü ödeyen bir şirkettir.
Anahtar bilgiler Toplam Hissedar Getirisi 1.3% Gelecekteki Temettü Verimi 1.1% Temettü Büyümesi -2.6% Bir sonraki temettü ödeme tarihi n/a Eski temettü tarihi n/a Hisse başına temettü US$26.000 Ödeme oranı 30%
Son temettü ve geri alım güncellemeleri Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million. Aug 30
Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million. Aug 10 Terumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 Terumo Corporation Announces Dividend for the Second Quarter End of Fiscal Year 2023, Commences Dividend Payments on December 5, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023 Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2023 Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.98% for ¥50,000 million.
Tüm güncellemeleri göster
Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024 Sep 25 Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million. Aug 30
Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024 Jun 02
Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring System May 29
Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024 Mar 17
Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 Feb 09 Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 Shinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024
Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024 Dec 03
Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023 Oct 01
Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million. Aug 10
Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023 Jun 21 Terumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024
Terumo Corporation, Annual General Meeting, Jun 27, 2023 May 16 Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 Terumo Corporation Announces Dividend for the Second Quarter End of Fiscal Year 2023, Commences Dividend Payments on December 5, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023 Nov 10
Terumo Corporation to Report Q2, 2023 Results on Nov 10, 2022 Sep 28
Mitsui DM Sugar Holdings Co.,Ltd. (TSE:2109) agreed to acquire Enteral formula business of Terumo Corporation from Terumo Corporation (TSE:4543). Sep 09
NUTRI Co.,Ltd. entered into an agreement to acquire Nutritional food and related product assets of Terumo Corporation. Sep 08 Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2023
Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan May 16 Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.98% for ¥50,000 million.
Terumo Corporation to Report Fiscal Year 2022 Results on May 12, 2022 Apr 08
Terumo Corporation, Annual General Meeting, Jun 22, 2022 Feb 10 Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022 Terumo Corporation Provides Dividend Guidance for the Year Ending March 2022
Terumo Corporation (TSE:4543) signed definitive agreement to acquire All Assets from Health Outcomes Sciences, Inc. Feb 25
Terumo Corporation Announces Clinical Study in Japan for Product Using Terumo's Automated Injection Device Developed in Collaboration with Kyowa Kirin Co., Ltd Feb 08
Terumo Corporation Revises Earnings Guidance for the Fourth Quarter of Fiscal 2021 Feb 06
IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand Jan 06
Terumo Corporation to Report Q3, 2021 Results on Feb 04, 2021 Dec 23
Diabeloop SA. and Terumo Corporation Enter into Joint Development Agreement with Exclusive Distribution Right for Dblg1 Automated Insulin Delivery Solution in Japanese Market Nov 17
IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million Oct 06
Terumo Corporation to Report Q2, 2021 Results on Nov 05, 2020 Sep 27
Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc. Aug 25
Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million. Jul 30 Terumo Corporation to Report Q1, 2021 Results on Aug 06, 2020 Jun 29
Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: TRUM.F şirketinin hisse başına düşen temettüsü son 10 yıldır istikrarlıydı.
Büyüyen Temettü: TRUM.F şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.
Piyasaya Karşı Temettü Getirisi Terumo Piyasaya Karşı Temettü Getirisi
TRUM.F temettü verimi piyasa ile karşılaştırıldığında nasıldır? Segment Temettü Verimi Şirket (TRUM.F) 0.9% Pazarın Alt %25'i (US) 1.4% Pazarın En İyi %25'i (US) 4.4% Sektör Ortalaması (Medical Equipment) 1.7% Analist tahmini (TRUM.F) (3 yıla kadar) 1.1%
Önemli Temettü: TRUM.F şirketinin temettüsü ( 0.86% ), US pazarındaki temettü ödeyenlerin en alttaki %25'ine ( 1.35% ) kıyasla dikkate değer değil.
Yüksek Temettü: TRUM.F 'in temettüsü ( 0.86% ), US piyasasındaki temettü ödeyenlerin en üst %25'ine ( 4.34% ) kıyasla düşüktür.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Oldukça düşük ödeme oranı ( 29.8% ) ile TRUM.F 'un temettü ödemeleri kazançlarla oldukça iyi bir şekilde karşılanıyor.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Oldukça düşük nakit ödeme oranı ( 33.7% ) ile TRUM.F 'un temettü ödemeleri nakit akışları tarafından iyi bir şekilde karşılanmaktadır.
Güçlü temettü ödeyen şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}